Skip to main content
SpringerLink
Log in

Current Management Strategies for Intraocular Retinoblastoma

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Survival rates for retinoblastoma patients have increased dramatically over the last century, with documented 5-year survival figures reaching 87–99% in developed countries. During the last decade, there has been a dramatic paradigm shift in the treatment approach for intraocular retinoblastoma, emphasising chemoreduction protocols and minimising the use of external beam radiation. The recognition of the increased risk for second non-ocular cancers with external beam radiation contributed to the growing emergence of chemotherapy. Although chemoreduction protocols vary slightly between institutions, many centres are currently treating intraocular retinoblastoma with carboplatin, vincristine and etoposide as a three-drug regimen given in two to six cycles. Clinical studies have demonstrated that systemic chemotherapy must be combined with other modalities, such as laser treatment and cryotherapy, for adequate tumour control and many eyes with advanced intraocular disease require salvage therapy with radiation or enucleation. Therefore, modern centres treating retinoblastoma continue to manage patients with a variety of modalities, individualising the therapy according to the patient’s presentation and clinical course.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gatta G, Capocaccia R, Coleman MP, et al. Childhood cancer survival in Europe and the United States. Cancer 2002; 95(8): 1767–72

    Article  PubMed  Google Scholar 

  2. Augsburger JJ, editor. Epidemiology of retinoblastoma. New York: Marcel Dekker, 2003: 49

    Google Scholar 

  3. Novakovic B. U.S. childhood cancer survival, 1973–1987. Med Pediatr Oncol 1994; 23(6): 480–6

    CAS  Google Scholar 

  4. Sant M, Capocaccia R, Badioni V. Survival for retinoblastoma in Europe. Eur J Cancer 2001; 37(6): 730–5

    Article  PubMed  CAS  Google Scholar 

  5. Mouratova T. Retinoblastoma in Uzbekistan. Bull Soc Belge Ophtalmol 2003; 289: 63–9

    PubMed  Google Scholar 

  6. Freedman J, Goldberg L. Incidence of retinoblastoma in the Bantu of South Africa. Br J Ophthalmol 1976; 60(9): 655–6

    Article  PubMed  CAS  Google Scholar 

  7. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Oto-laryngol 1963; 67: 164–72

    CAS  Google Scholar 

  8. Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc 2004; 102: 35–44

    PubMed  Google Scholar 

  9. Murphree AL. Intraocular retinoblastoma: a case for a new group classification. Ophthalmol Clin North Am 2005; 18: 41–53

    Article  Google Scholar 

  10. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113(12): 2276–80

    Article  PubMed  Google Scholar 

  11. Abramson DH, Schefler AC. Update on retinoblastoma. Retina 2004; 24(6): 828–48

    Article  PubMed  Google Scholar 

  12. Demirci H, Shields CL, Meadows AT, et al. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 2005; 123(11): 1525–30

    Article  PubMed  Google Scholar 

  13. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114(11): 1330–8

    Article  PubMed  CAS  Google Scholar 

  14. Murphree AL, Villablanca JG, Deegan III WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114(11): 1348–56

    Article  PubMed  CAS  Google Scholar 

  15. Shields JA, Shields CL, De Potter P, et al. Bilateral macular retinoblastoma managed by chemoreduction and chemother-motherapy. Arch Ophthalmol 1996; 114(11): 1426–7

    Article  PubMed  CAS  Google Scholar 

  16. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997; 104(12): 2101–11

    PubMed  CAS  Google Scholar 

  17. Greenwald MJ, Goldman S, Strauss LC. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1998; 105(9): 1579–81

    Article  PubMed  CAS  Google Scholar 

  18. Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114(11): 1339–43

    Article  PubMed  CAS  Google Scholar 

  19. Gunduz K, Shields CL, Shields JA, et al. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Arch Ophthalmol 1998; 116(12): 1613–7

    PubMed  CAS  Google Scholar 

  20. Bornfeld N, Schuler A, Bechrakis N, et al. Preliminary results of primary chemotherapy in retinoblastoma. Klin Padiatr 1997; 209(4): 216–21

    Article  PubMed  CAS  Google Scholar 

  21. Brichard B, De Bruycker JJ, De Potter P, et al. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol 2002; 38(6): 411–5

    Article  PubMed  Google Scholar 

  22. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18(1): 12–7

    PubMed  CAS  Google Scholar 

  23. Antoneli CB, Ribeiro KC, Steinhorst F, et al. Treatment of retinoblastoma patients with chemoreduction plus local therapy: experience of the AC Camargo Hospital, Brazil. J Pediatr Hematol Oncol 2006; 28(6): 342–5

    Article  PubMed  CAS  Google Scholar 

  24. Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients. Cancer 1994; 74(2): 722–32

    Article  PubMed  CAS  Google Scholar 

  25. Goble RR, McKenzie J, Kingston JE, et al. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol 1990; 74(2): 97–8

    Article  PubMed  CAS  Google Scholar 

  26. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996; 2(9): 1499–508

    PubMed  CAS  Google Scholar 

  27. Chan HS, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res 1989; 9(2): 469–74

    PubMed  CAS  Google Scholar 

  28. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114(11): 1321–8

    Article  PubMed  CAS  Google Scholar 

  29. Beck MN, Balmer A, Dessing C, et al. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000; 18(15): 2881–7

    PubMed  CAS  Google Scholar 

  30. Schiavetti A, Hadjistilianou T, Clerico A, et al. Conservative therapy in intraocular retinoblastoma: response/recurrence rate. J Pediatr Hematol Oncol 2005; 27(1): 3–6

    Article  PubMed  Google Scholar 

  31. Wilson MW, Rodriguez-Galindo C, Haik BG, et al. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 2001; 108(11): 2106–14

    Article  PubMed  CAS  Google Scholar 

  32. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003; 21(10): 2019–25

    Article  PubMed  CAS  Google Scholar 

  33. Lee TC, Hayashi NI, Dunkel IJ, et al. New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 2003; 110(10): 1989–94; discussion 94-5

    Article  PubMed  Google Scholar 

  34. Abramson DH, Lawrence SD, Beaverson KL, et al. Systemic carboplatin for retinoblastoma: change in tumour size over time. Br J Ophthalmol 2005; 89(12): 1616–9

    Article  PubMed  CAS  Google Scholar 

  35. Shields CL, Honavar SG, Shields JA, et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002; 120(4): 460–4

    Article  PubMed  Google Scholar 

  36. Abramson DH, Beaverson KL, Chang ST, et al. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol 2004; 122(9): 1316–23

    Article  PubMed  Google Scholar 

  37. Shields CL, Shields JA, DePotter P, et al. The effect of chemoreduction on retinoblastoma-induced retinal detachment. J Pediatr Ophthalmol Strabismus 1997; 34(3): 165–9

    PubMed  CAS  Google Scholar 

  38. Gombos DS, Kelly A, Coen PG, et al. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 2002; 86(1): 80–3

    Article  PubMed  Google Scholar 

  39. Abramson DH, Gamell LS, Ellsworth RM, et al. Unilateral retinoblastoma: new intraocular tumours after treatment. Br J Ophthalmol 1994; 78(9): 698–701

    Article  PubMed  CAS  Google Scholar 

  40. Abramson DH, Greenfield DS, Ellsworth RM. Bilateral retinoblastoma: correlations between age at diagnosis and time course for new intraocular tumors. Ophthalmic Paediatr Genet 1992; 13(1): 1–7

    Article  PubMed  CAS  Google Scholar 

  41. Smits C, Swen SJ, Theo Goverts S, et al. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 2006; 42(4): 492–500

    Article  PubMed  CAS  Google Scholar 

  42. Anagnoste SR, Scott IU, Murray TG, et al. Rhegmatogenous retinal detachment in retinoblastoma patients undergoing chemoreduction and cryotherapy. Am J Ophthalmol 2000; 129(6): 817–9

    Article  PubMed  CAS  Google Scholar 

  43. Gombos DS, Howes E, O’Brien JM. Cholesterosis following chemoreduction for advanced retinoblastoma. Arch Ophthalmol 2000; 118(3): 440–1

    PubMed  CAS  Google Scholar 

  44. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325(24): 1682–7

    Article  PubMed  CAS  Google Scholar 

  45. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007 Jul; 114(7): 1378–83

    Article  PubMed  Google Scholar 

  46. Abramson DH, Ellsworth RM, Kitchin FD, et al. Second no-nocular tumors in retinoblastoma survivors: are they radiation-induced? Ophthalmology 1984; 91(11): 1351–5

    PubMed  CAS  Google Scholar 

  47. Mendelsohn ME, Abramson DH, Madden T, et al. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 1998; 116(9): 1209–12

    PubMed  CAS  Google Scholar 

  48. Murray TG, Cicciarelli N, O’Brien JM, et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of trans-genic murine retinoblastoma. Arch Ophthalmol 1997; 115(10): 1286–90

    Article  PubMed  CAS  Google Scholar 

  49. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999; 106(10): 1947–50

    Article  PubMed  CAS  Google Scholar 

  50. Schmack I, Hubbard GB, Kang SJ, et al. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006; 142(2): 310–5

    Article  PubMed  CAS  Google Scholar 

  51. Caraceni A, Martini C, Spatti G, et al. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand 1997; 96(4): 260–1

    Article  PubMed  CAS  Google Scholar 

  52. Wang MY, Arnold AC, Vinters HV, et al. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol 2000; 130(3): 367–8

    Article  PubMed  CAS  Google Scholar 

  53. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 2003; 121(8): 1120–4

    Article  PubMed  CAS  Google Scholar 

  54. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997. Is there an age effect on radiation-related risk? Ophthalmology 2001; 108(6): 1109–14

    Article  PubMed  CAS  Google Scholar 

  55. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85(14): 1121–8

    Article  PubMed  CAS  Google Scholar 

  56. Wong FL, Boice Jr JD, Abramson DH, et al. Cancer incidence after retinoblastoma.Radiation dose and sarcoma risk. JAMA 1997; 278(15): 1262–7

    Article  PubMed  CAS  Google Scholar 

  57. Aerts I, Pacquement H, Doz F, et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 2004; 40(10): 1522–9

    Article  PubMed  Google Scholar 

  58. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23(10): 2272–9

    Article  PubMed  Google Scholar 

  59. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 1998; 105(4): 573–9

    Article  PubMed  CAS  Google Scholar 

  60. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96(5): 357–63

    Article  PubMed  Google Scholar 

  61. McCormick B, Ellsworth R, Abramson D, et al. Radiation therapy for retinoblastoma: comparison of results with lens-sparing versus lateral beam techniques. Int J Radiat Oncol Biol Phys 1988; 15(3): 567–74

    Article  PubMed  CAS  Google Scholar 

  62. McCormick B, Ellsworth R, Abramson D, et al. Results of external beam radiation for children with retinoblastoma: a comparison of two techniques. J Pediatr Ophthalmol Strabismus 1989; 26(5): 239–43

    PubMed  CAS  Google Scholar 

  63. Zelter M, Damel A, Gonzalez G, et al. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer 1991; 68(8): 1685–90

    Article  PubMed  CAS  Google Scholar 

  64. Shidnia H, Hornback NB, Helveston EM, et al. Treatment results of retinoblastoma at Indiana University Hospitals. Cancer 1977; 40(6): 2917–22

    Article  PubMed  CAS  Google Scholar 

  65. Foote RL, Garretson BR, Schomberg PJ, et al. External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis. Int J Radiat Oncol Biol Phys 1989; 16(3): 823–30

    Article  PubMed  CAS  Google Scholar 

  66. Abramson DH, Jereb B, Ellsworth RM. External beam radiation for retinoblastoma. Bull N Y Acad Med 1981; 57(9): 787–803

    PubMed  CAS  Google Scholar 

  67. Abramson DH, Ellsworth RM, Tretter P, et al. Treatment of bilateral groups I through III retinoblastoma with bilateral radiation. Arch Ophthalmol 1981; 99(10): 1761–2

    Article  PubMed  CAS  Google Scholar 

  68. Ellsworth RM. Retinoblastoma. Mod Probl Ophthalmol 1977; 18: 94–100

    PubMed  CAS  Google Scholar 

  69. Hungerford JL, Toma NM, Plowman PN, et al. Whole-eye versus lens-sparing megavoltage therapy for retinoblastoma. Front Radiat Ther Oncol 1997; 30: 81–7

    PubMed  CAS  Google Scholar 

  70. Fontanesi J, Pratt CB, Kun LE, et al. Treatment outcome and dose-response relationship in infants younger than 1 year treated for retinoblastoma with primary irradiation. Med Pediatr Oncol 1996; 26(5): 297–304

    Article  PubMed  CAS  Google Scholar 

  71. Abramson DH, editor. Treatment of retinoblastoma. New York: Churchill Livingston, 1985: 3–93

    Google Scholar 

  72. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 2001; 108(11): 2116–21

    Article  PubMed  CAS  Google Scholar 

  73. Schueler AO, Fluhs D, Anastassiou G, et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. Int J Radiat Oncol Biol Phys 2006; 65(4): 1212–21

    Article  PubMed  Google Scholar 

  74. Buys RJ, Abramson DH, Ellsworth RM, et al. Radiation regression patterns after cobalt plaque insertion for retinoblastoma. Arch Ophthalmol 1983; 101(8): 1206–8

    Article  PubMed  CAS  Google Scholar 

  75. Merchant TE, Gould CJ, Wilson MW, et al. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer 2004; 43(2): 134–9

    Article  PubMed  Google Scholar 

  76. Abramson DH, Ellsworth RM. The surgical management of retinoblastoma. Ophthalmic Surg 1980; 11(9): 596–8

    PubMed  CAS  Google Scholar 

  77. Tawfik HA. Superomedial lid crease approach to the medial intraconal space. Ophthal Plast Reconstr Surg 2002; 18(2): 164–5

    Article  PubMed  Google Scholar 

  78. Abramson DH, Schefler AC, Almeida D, et al. Optic nerve tissue shrinkage during pathologic processing after enucleation for retinoblastoma. Arch Ophthalmol 2003; 121(1): 73–5

    Article  PubMed  Google Scholar 

  79. Kim JW, Kikkawa DO, Aboy A, et al. Chronic exposure of hydroxyapatite orbital implants: cilia implantation and epithelial downgrowth. Ophthal Plast Reconstr Surg 2000; 16(3): 216–22

    Article  PubMed  CAS  Google Scholar 

  80. Hungerford J, Kingston J, Plowman N. Orbital recurrence of retinoblastoma. Ophthalmic Paediatr Genet 1987; 8(1): 63–8

    Article  PubMed  CAS  Google Scholar 

  81. Hungerford J. Factors influencing metastasis in retinoblastoma [comment]. Br J Ophthalmol 1993; 77(9): 541

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmic Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, A-330, New York, New York, 10021, USA

    Jonathan W. Kim & David H. Abramson

  2. Department of Pediatric Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA

    Ira J. Dunkel

Authors
  1. Jonathan W. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David H. Abramson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ira J. Dunkel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan W. Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.W., Abramson, D.H. & Dunkel, I.J. Current Management Strategies for Intraocular Retinoblastoma. Drugs 67, 2173–2185 (2007). https://doi.org/10.2165/00003495-200767150-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767150-00005

Keywords

Search

Navigation